Publications 2023

Høland M, Berg KCG, Eilertsen IA, Bjerkehagen B, Kolberg M, Boye K, Lingjærde OC, Guren TK, Mandahl N, van den Berg E, Palmerini E, Smeland S, Picci P, Mertens F, Sveen A, Lothe RA (2023)
Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets
EBioMedicine, 97, 104829
DOI 10.1016/j.ebiom.2023.104829, PubMed 37837931

Oh DY, Algazi A, Capdevila J, Longo F, Miller W, Chun Bing JT, Bonilla CE, Chung HC, Guren TK, Lin CC, Motola-Kuba D, Shah M, Hadoux J, Yao L, Jin F, Norwood K, Lebellec L (2023)
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study
Cancer, 129 (8), 1195-1204
DOI 10.1002/cncr.34657, PubMed 36748723

Publications 2022

Callesen LB, Hamfjord J, Boysen AK, Pallisgaard N, Guren TK, Kure EH, Spindler KG (2022)
Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis
Br J Cancer, 127 (3), 500-513
DOI 10.1038/s41416-022-01816-4, PubMed 35440666

Carlsson G, Koumarianou A, Guren TK, Haux J, Katsaounis P, Kentepozidis N, Pfeiffer P, Brændengen M, Mavroudis D, Taflin H, Skintemo L, Tell R, Papadimitriou C (2022)
A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer
ESMO Open, 7 (5), 100589
DOI 10.1016/j.esmoop.2022.100589, PubMed 36183444

Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Belani A, Zhang X, Tabernero J (2022)
Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC
ESMO Open, 7 (3), 100477
DOI 10.1016/j.esmoop.2022.100477, PubMed 35653981

Kryeziu K, Bergsland CH, Guren TK, Sveen A, Lothe RA (2022)
Multiplex immunohistochemistry of metastatic colorectal cancer and ex vivo tumor avatars
Biochim Biophys Acta Rev Cancer, 1877 (1), 188682
DOI 10.1016/j.bbcan.2022.188682, PubMed 35065193

Marabelle A, Cassier PA, Fakih M, Kao S, Nielsen D, Italiano A, Guren TK, van Dongen MGJ, Spencer K, Bariani GM, Ascierto PA, Santoro A, Shah M, Asselah J, Iqbal S, Takahashi S, Piha-Paul SA, Ott PA, Chatterjee A, Jin F, Norwood K, Delord JP (2022)
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study
Lancet Gastroenterol Hepatol, 7 (5), 446-454
DOI 10.1016/S2468-1253(21)00382-4, PubMed 35114169

Smedman TM, Guren TK, Tveit KM, Thomsen M, Andersen MH, Line PD, Dueland S (2022)
Health-Related Quality of Life in Colorectal Cancer Patients Treated With Liver Transplantation Compared to Chemotherapy
Transpl Int, 35, 10404
DOI 10.3389/ti.2022.10404, PubMed 35707633

Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES, CONNECT Public–Private Partnership Consortium, Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R, InPreD-Norway and National Molecular Tumor Board Consortium, IMPRESS-Norway Consortium, Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å (2022)
A national precision cancer medicine implementation initiative for Norway
Nat Med, 28 (5), 885-887
DOI 10.1038/s41591-022-01777-4, PubMed 35513529

Aamdal E, Skovlund E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Hagene KT, Holmsen K, Aamdal S, Kaasa S, Guren TK, Kyte JA (2022)
Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment
ESMO Open, 7 (5), 100588
DOI 10.1016/j.esmoop.2022.100588, PubMed 36116420

Publications 2021

Hamfjord J, Guren TK, Glimelius B, Sorbye H, Pfeiffer P, Dajani O, Lingjaerde OC, Tveit KM, Pallisgaard N, Spindler KG, Kure EH (2021)
Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer
Int J Cancer, 149 (6), 1385-1397
DOI 10.1002/ijc.33672, PubMed 33961700

Hamfjord J, Myklebust TÅ, Larsen IK, Kure EH, Glimelius B, Guren TK, Tveit KM, Guren MG (2021)
Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study
Cancer Epidemiol Biomarkers Prev, 31 (2), 342-351
DOI 10.1158/1055-9965.EPI-21-0555, PubMed 34853022

Robbrecht D, Jungels C, Sorensen MM, Spanggaard I, Eskens F, Fretland SØ, Guren TK, Aftimos P, Liberg D, Svedman C, Thorsson L, Steeghs N, Awada A (2021)
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours
Br J Cancer, 126 (7), 1010-1017
DOI 10.1038/s41416-021-01657-7, PubMed 34903842

Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S (2021)
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
J Clin Oncol, 39 (4), 273-284
DOI 10.1200/JCO.20.02088, PubMed 33503393

Yap TA, Nakagawa K, Fujimoto N, Kuribayashi K, Guren TK, Calabrò L, Shapira-Frommer R, Gao B, Kao S, Matos I, Planchard D, Chatterjee A, Jin F, Norwood K, Kindler HL (2021)
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
Lancet Respir Med, 9 (6), 613-621
DOI 10.1016/S2213-2600(20)30515-4, PubMed 33836153

Aamdal E, Inderberg EM, Ellingsen EB, Rasch W, Brunsvig PF, Aamdal S, Heintz KM, Vodák D, Nakken S, Hovig E, Nyakas M, Guren TK, Gaudernack G (2021)
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
Front Immunol, 12, 663865
DOI 10.3389/fimmu.2021.663865, PubMed 34046035

Aamdal E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Schuster C, Hagene KT, Holmsen K, Russnes HG, Skovlund E, Kaasa S, Aamdal S, Kyte JA, Guren TK (2021)
Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up
Int J Cancer, 150 (1), 100-111
DOI 10.1002/ijc.33768, PubMed 34449877

Publications 2020

Brunsvig PF, Guren TK, Nyakas M, Steinfeldt-Reisse CH, Rasch W, Kyte JA, Juul HV, Aamdal S, Gaudernack G, Inderberg EM (2020)
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
Front Immunol, 11, 572172
DOI 10.3389/fimmu.2020.572172, PubMed 33324397

Publications 2019

Hamfjord J, Guren TK, Dajani O, Johansen JS, Glimelius B, Sorbye H, Pfeiffer P, Lingjærde OC, Tveit KM, Kure EH, Pallisgaard N, Spindler KG (2019)
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy
Ann Oncol, 30 (7), 1088-1095
DOI 10.1093/annonc/mdz139, PubMed 31046124

Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A et al. (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
N Engl J Med, 381 (17), 1632-1643
DOI 10.1056/NEJMoa1908075, PubMed 31566309

Kryeziu K, Bruun J, Guren TK, Sveen A, Lothe RA (2019)
Combination therapies with HSP90 inhibitors against colorectal cancer
Biochim Biophys Acta Rev Cancer, 1871 (2), 240-247
DOI 10.1016/j.bbcan.2019.01.002, PubMed 30708039

Nathan P, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, Guida M, Lorigan P, Chiarion-Sileni V, Gogas H, Maio M, Fierro MT, Hoeller C, Terheyden P, Gutzmer R, Guren TK, Bafaloukos D, Rutkowski P, Plummer R, Waterston A, Kaatz M, Mandala M, Marquez-Rodas I, Muñoz-Couselo E, Dummer R et al. (2019)
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Eur J Cancer, 119, 168-178
DOI 10.1016/j.ejca.2019.07.010, PubMed 31445199

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848

Schadendorf D, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, Guida M, Lorigan P, Chiarion-Sileni V, Gogas H, Maio M, Fierro MT, Hoeller C, Terheyden P, Gutzmer R, Guren TK, Bafaloukos D, Rutkowski P, Plummer R, Waterston A, Kaatz M, Mandala M, Marquez-Rodas I, Muñoz-Couselo E, Dummer R et al. (2019)
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
Eur J Cancer, 121, 144-153
DOI 10.1016/j.ejca.2019.08.014, PubMed 31581055

Smedman TM, Guren TK, Line PD, Dueland S (2019)
Transplant oncology: assessment of response and tolerance to systemic chemotherapy for metastatic colorectal cancer after liver transplantation - a retrospective study
Transpl Int, 32 (11), 1144-1150
DOI 10.1111/tri.13471, PubMed 31209941

Publications 2018

Smedman TM, Line PD, Guren TK, Dueland S (2018)
Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients
Acta Oncol, 57 (10), 1414-1418
DOI 10.1080/0284186X.2018.1479069, PubMed 29912605

Thomsen M, Skovlund E, Sorbye H, Bolstad N, Nustad KJ, Glimelius B, Pfeiffer P, Kure EH, Johansen JS, Tveit KM, Christoffersen T, Guren TK (2018)
Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
Br J Cancer, 118 (12), 1609-1616
DOI 10.1038/s41416-018-0115-9, PubMed 29872151

Publications 2017

Dueland S, Guren TK, Boberg KM, Reims HM, Grzyb K, Aamdal S, Julsrud L, Line PD (2017)
Acute liver graft rejection after ipilimumab therapy
Ann Oncol, 28 (10), 2619-2620
DOI 10.1093/annonc/mdx281, PubMed 28961840

Guren TK, Thomsen M, Kure EH, Sorbye H, Glimelius B, Pfeiffer P, Österlund P, Sigurdsson F, Lothe IMB, Dalsgaard AM, Skovlund E, Christoffersen T, Tveit KM (2017)
Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
Br J Cancer, 116 (10), 1271-1278
DOI 10.1038/bjc.2017.93, PubMed 28399112

Mezheyeuski A, Strell C, Hrynchyk I, Guren TK, Dragomir A, Doroshenko T, Pashkova O, Gorgun J, Ruksha K, Pfeiffer P, Kure EH, Sorbye H, Edler D, Martling A, Glimelius B, Östman A, Portyanko A (2017)
Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer
Virchows Arch, 472 (3), 395-405
DOI 10.1007/s00428-017-2263-3, PubMed 29134439

Thomsen M, Guren MG, Skovlund E, Glimelius B, Hjermstad MJ, Johansen JS, Kure E, Sorbye H, Pfeiffer P, Christoffersen T, Guren TK, Tveit KM (2017)
Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status
Eur J Cancer, 81, 26-35
DOI 10.1016/j.ejca.2017.04.026, PubMed 28595137

Ødegård J, Sondresen JE, Aasrum M, Tveteraas IH, Guren TK, Christoffersen T, Thoresen GH (2017)
Differential effects of epidermal growth factor (EGF) receptor ligands on receptor binding, downstream signalling pathways and DNA synthesis in hepatocytes
Growth Factors, 35 (6), 239-248
DOI 10.1080/08977194.2018.1453506, PubMed 29582692

Publications 2016

Mezheyeuski A, Bradic Lindh M, Guren TK, Dragomir A, Pfeiffer P, Kure EH, Ikdahl T, Skovlund E, Corvigno S, Strell C, Pietras K, Ponten F, Mulder J, Qvortrup C, Portyanko A, Tveit KM, Glimelius B, Sorbye H, Östman A (2016)
Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer
Oncotarget, 7 (27), 41948-41958
DOI 10.18632/oncotarget.9632, PubMed 27248825

Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frodin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Watkins DJ (2016)
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial
Int J Cancer, 140 (2), 431-439
DOI 10.1002/ijc.30453, PubMed 27681944

Tarpgaard LS, Ørum-Madsen MS, Christensen IJ, Nordgaard C, Noer J, Guren TK, Glimelius B, Sorbye H, Ikdahl T, Kure EH, Tveit KM, Nielsen HJ, Pfeiffer P, Brünner N, Moreira JM (2016)
TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer
Oncotarget, 7 (37), 59441-59457
DOI 10.18632/oncotarget.11118, PubMed 27509063

Thomsen M, Kersten C, Sorbye H, Skovlund E, Glimelius B, Pfeiffer P, Johansen JS, Kure EH, Ikdahl T, Tveit KM, Christoffersen T, Guren TK (2016)
Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
Oncotarget, 7 (46), 75013-75022
DOI 10.18632/oncotarget.12601, PubMed 27738330

Publications 2015

Dueland S, Guren TK, Hagness M, Glimelius B, Line PD, Pfeiffer P, Foss A, Tveit KM (2015)
Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer?
Ann Surg, 261 (5), 956-60
DOI 10.1097/SLA.0000000000000786, PubMed 24950280

Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frödin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Mauro DJ, Watkins DJ (2015)
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer
J Natl Cancer Inst, 107 (12), djv258
DOI 10.1093/jnci/djv258, PubMed 26405092

Tarpgaard LS, Christensen IJ, Høyer-Hansen G, Lund IK, Guren TK, Glimelius B, Sorbye H, Tveit KM, Nielsen HJ, Moreira JM, Pfeiffer P, Brünner N (2015)
Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab
Int J Cancer, 137 (10), 2470-7
DOI 10.1002/ijc.29476, PubMed 25664394

Publications 2014

Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E, Lothe RA (2014)
Portrait of the PI3K/AKT pathway in colorectal cancer
Biochim Biophys Acta, 1855 (1), 104-21
DOI 10.1016/j.bbcan.2014.09.008, PubMed 25450577

Dueland S, Hagness M, Line PD, Guren TK, Tveit KM, Foss A (2014)
Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy?
Ann Surg Oncol, 22 (7), 2195-200
DOI 10.1245/s10434-014-4137-0, PubMed 25297902

Tarpgaard LS, Guren TK, Glimelius B, Christensen IJ, Pfeiffer P, Kure EH, Sorbye H, Ikdahl T, Yilmaz M, Johansen JS, Tveit KM (2014)
Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study
PLoS One, 9 (2), e87746
DOI 10.1371/journal.pone.0087746, PubMed 24498368

Publications 2009

Christoffersen T, Guren TK, Spindler KL, Dahl O, Lønning PE, Gjertsen BT (2009)
Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues
Eur J Pharmacol, 625 (1-3), 6-22
DOI 10.1016/j.ejphar.2009.10.009, PubMed 19836383

Publications 2008

Dajani OF, Meisdalen K, Guren TK, Aasrum M, Tveteraas IH, Lilleby P, Thoresen GH, Sandnes D, Christoffersen T (2008)
Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes
J Cell Physiol, 214 (2), 371-80
DOI 10.1002/jcp.21205, PubMed 17654493

Publications 2005

Guren TK, Christoffersen T, Thoresen GH, Wisløff F, Dajani O, Tveit KM (2005)
[Antineoplastic agents targeting tyrosine kinases]
Tidsskr Nor Laegeforen, 125 (22), 3115-9
PubMed 16299568

Publications 2003

Guren TK, Ødegård J, Abrahamsen H, Thoresen GH, Susa M, Andersson Y, Østby E, Christoffersen T (2003)
EGF receptor-mediated, c-Src-dependent, activation of Stat5b is downregulated in mitogenically responsive hepatocytes
J Cell Physiol, 196 (1), 113-23
DOI 10.1002/jcp.10282, PubMed 12767047

Thoresen GH, Guren TK, Christoffersen T (2003)
Role of ERK, p38 and PI3-kinase in EGF receptor-mediated mitogenic signalling in cultured rat hepatocytes: requirement for sustained ERK activation
Cell Physiol Biochem, 13 (4), 229-38
DOI 10.1159/000072426, PubMed 12876381

Publications 2002

Guren TK (2002)
Signal transduction pathways from the epidermal growth factor receptor in hepatocytes
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 53, 1 b. (flere pag.)
BIBSYS 022376216, ISBN 82-8072-013-8

Publications 2000

Skarpen E, Lindeman B, Thoresen GH, Guren TK, Oksvold MP, Christoffersen T, Huitfeldt HS (2000)
Impaired nuclear accumulation and shortened phosphorylation of ERK after growth factor stimulation in cultured hepatocytes from rats exposed to 2-acetylaminofluorene
Mol Carcinog, 28 (2), 84-96
DOI 10.1002/1098-2744(200006)28:2<84::aid-mc4>3.0.co;2-x, PubMed 10900465

Publications 1999

Guren TK, Abrahamsen H, Thoresen GH, Babaie E, Berg T, Christoffersen T (1999)
EGF-induced activation of Stat1, Stat3, and Stat5b is unrelated to the stimulation of DNA synthesis in cultured hepatocytes
Biochem Biophys Res Commun, 258 (3), 565-71
DOI 10.1006/bbrc.1999.0684, PubMed 10329425

Publications 1998

Skarpen E, Johannessen LE, Bjerk K, Fasteng H, Guren TK, Lindeman B, Thoresen GH, Christoffersen T, Stang E, Huitfeldt HS, Madshus IH (1998)
Endocytosed epidermal growth factor (EGF) receptors contribute to the EGF-mediated growth arrest in A431 cells by inducing a sustained increase in p21/CIP1
Exp Cell Res, 243 (1), 161-72
DOI 10.1006/excr.1998.4127, PubMed 9716460

Thoresen GH, Guren TK, Sandnes D, Peak M, Agius L, Christoffersen T (1998)
Response to transforming growth factor alpha (TGFalpha) and epidermal growth factor (EGF) in hepatocytes: lower EGF receptor affinity of TGFalpha is associated with more sustained activation of p42/p44 mitogen-activated protein kinase and greater efficacy in stimulation of DNA synthesis
J Cell Physiol, 175 (1), 10-8
DOI 10.1002/(SICI)1097-4652(199804)175:1<10::AID-JCP2>3.0.CO;2-F, PubMed 9491776

Publications 1996

Guren TK, Thoresen GH, Dajani OF, Taraldsrud E, Moberg ER, Christoffersen T (1996)
Epidermal growth factor behaves as a partial agonist in hepatocytes: effects on DNA synthesis in primary culture and competition with transforming growth factor alpha
Growth Factors, 13 (3-4), 171-9
DOI 10.3109/08977199609003219, PubMed 8919025

Publications 1994

Dajani OF, Refsnes M, Guren TK, Horn RS, Thoresen GH, Christoffersen T (1994)
Elevated glucose concentrations inhibit DNA synthesis and expression of c-myc in cultured hepatocytes
Biochem Biophys Res Commun, 202 (3), 1476-82
DOI 10.1006/bbrc.1994.2097, PubMed 8060330

Publications 1990

Thoresen GH, Sand TE, Refsnes M, Dajani OF, Guren TK, Gladhaug IP, Killi A, Christoffersen T (1990)
Dual effects of glucagon and cyclic AMP on DNA synthesis in cultured rat hepatocytes: stimulatory regulation in early G1 and inhibition shortly before the S phase entry
J Cell Physiol, 144 (3), 523-30
DOI 10.1002/jcp.1041440321, PubMed 2167904